Brentuximab Vedotin
Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (i) patients with Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or aft...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2013, Vol.19 (1), p.22-27 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 27 |
|---|---|
| container_issue | 1 |
| container_start_page | 22 |
| container_title | Clinical cancer research |
| container_volume | 19 |
| creator | Deng, Changchun Pan, Beiqing O'Connor, Owen A |
| description | Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (i) patients with Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or after two multidrug regimens in patients with Hodgkin lymphoma who are not candidates for ASCT; and (ii) patients with systemic anaplastic large cell lymphoma (ALCL) who failed at least one prior multidrug chemotherapy regimen. Patients with Hodgkin lymphoma and ALCL treated with brentuximab vedotin showed markedly high response rates for a single agent, exceeding 70% and 80% for Hodgkin lymphoma and ALCL, respectively. The complete response rate was equally as impressive, at 34% and 57% for Hodgkin lymphoma and ALCL, respectively. Results like these and from many other upcoming clinical trials, in which brentuximab vedotin is being investigated in the frontline setting, promise to profoundly change how we manage the CD30-positive lymphoproliferative malignancies. The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against Hodgkin lymphoma, ALCL, and other CD30-expressing lymphomas are reviewed. |
| doi_str_mv | 10.1158/1078-0432.ccr-12-0290 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273200111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273200111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-1b7390e5d0ed65263b162231b341a1a5edd99b2c6d5246569ab0238f56a388853</originalsourceid><addsrcrecordid>eNpFkEtLxDAUhYMozji6cq24EdxkzM2r6VKLLxgQRN2GvAqVTjsmLei_N8UZXd27-M659xyEzoAsAYS6BlIoTDijS-ciBooJLckemoMQBWZUiv2875gZOkrpgxDgQPghmlGWMVByjk5vY-iG8atZG3vxHnw_NN0xOqhNm8LJdi7Q2_3da_WIV88PT9XNCjtOxIDBFqwkQXgSvBRUMguSZmfLOBgwInhflpY66QXlUsjSWEKZqoU0TCkl2AJd_fpuYv85hjTodZNcaFvThX5MGmjBaH4aIKPiF3WxTymGWm9ifjl-ayB66kNPWfWUVVfVS5bqqY-sO9-eGO06-D_VroAMXG4Bk5xp62g616R_riCiUFyyH8r-ZS8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273200111</pqid></control><display><type>article</type><title>Brentuximab Vedotin</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Deng, Changchun ; Pan, Beiqing ; O'Connor, Owen A</creator><creatorcontrib>Deng, Changchun ; Pan, Beiqing ; O'Connor, Owen A</creatorcontrib><description>Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (i) patients with Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or after two multidrug regimens in patients with Hodgkin lymphoma who are not candidates for ASCT; and (ii) patients with systemic anaplastic large cell lymphoma (ALCL) who failed at least one prior multidrug chemotherapy regimen. Patients with Hodgkin lymphoma and ALCL treated with brentuximab vedotin showed markedly high response rates for a single agent, exceeding 70% and 80% for Hodgkin lymphoma and ALCL, respectively. The complete response rate was equally as impressive, at 34% and 57% for Hodgkin lymphoma and ALCL, respectively. Results like these and from many other upcoming clinical trials, in which brentuximab vedotin is being investigated in the frontline setting, promise to profoundly change how we manage the CD30-positive lymphoproliferative malignancies. The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against Hodgkin lymphoma, ALCL, and other CD30-expressing lymphomas are reviewed.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.ccr-12-0290</identifier><identifier>PMID: 23155186</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Animals ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic agents ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Clinical Trials, Phase II as Topic ; Drug Evaluation, Preclinical ; Hematopoietic Stem Cell Transplantation ; Hodgkin Disease - drug therapy ; Hodgkin Disease - therapy ; Humans ; Immunoconjugates - administration & dosage ; Immunoconjugates - adverse effects ; Immunoconjugates - therapeutic use ; Ki-1 Antigen - immunology ; Medical sciences ; Pharmacology. Drug treatments ; Recurrence ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Clinical cancer research, 2013, Vol.19 (1), p.22-27</ispartof><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-1b7390e5d0ed65263b162231b341a1a5edd99b2c6d5246569ab0238f56a388853</citedby><cites>FETCH-LOGICAL-c405t-1b7390e5d0ed65263b162231b341a1a5edd99b2c6d5246569ab0238f56a388853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27057846$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23155186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deng, Changchun</creatorcontrib><creatorcontrib>Pan, Beiqing</creatorcontrib><creatorcontrib>O'Connor, Owen A</creatorcontrib><title>Brentuximab Vedotin</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (i) patients with Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or after two multidrug regimens in patients with Hodgkin lymphoma who are not candidates for ASCT; and (ii) patients with systemic anaplastic large cell lymphoma (ALCL) who failed at least one prior multidrug chemotherapy regimen. Patients with Hodgkin lymphoma and ALCL treated with brentuximab vedotin showed markedly high response rates for a single agent, exceeding 70% and 80% for Hodgkin lymphoma and ALCL, respectively. The complete response rate was equally as impressive, at 34% and 57% for Hodgkin lymphoma and ALCL, respectively. Results like these and from many other upcoming clinical trials, in which brentuximab vedotin is being investigated in the frontline setting, promise to profoundly change how we manage the CD30-positive lymphoproliferative malignancies. The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against Hodgkin lymphoma, ALCL, and other CD30-expressing lymphomas are reviewed.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Drug Evaluation, Preclinical</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - therapy</subject><subject>Humans</subject><subject>Immunoconjugates - administration & dosage</subject><subject>Immunoconjugates - adverse effects</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Ki-1 Antigen - immunology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLxDAUhYMozji6cq24EdxkzM2r6VKLLxgQRN2GvAqVTjsmLei_N8UZXd27-M659xyEzoAsAYS6BlIoTDijS-ciBooJLckemoMQBWZUiv2875gZOkrpgxDgQPghmlGWMVByjk5vY-iG8atZG3vxHnw_NN0xOqhNm8LJdi7Q2_3da_WIV88PT9XNCjtOxIDBFqwkQXgSvBRUMguSZmfLOBgwInhflpY66QXlUsjSWEKZqoU0TCkl2AJd_fpuYv85hjTodZNcaFvThX5MGmjBaH4aIKPiF3WxTymGWm9ifjl-ayB66kNPWfWUVVfVS5bqqY-sO9-eGO06-D_VroAMXG4Bk5xp62g616R_riCiUFyyH8r-ZS8</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Deng, Changchun</creator><creator>Pan, Beiqing</creator><creator>O'Connor, Owen A</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2013</creationdate><title>Brentuximab Vedotin</title><author>Deng, Changchun ; Pan, Beiqing ; O'Connor, Owen A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-1b7390e5d0ed65263b162231b341a1a5edd99b2c6d5246569ab0238f56a388853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Drug Evaluation, Preclinical</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - therapy</topic><topic>Humans</topic><topic>Immunoconjugates - administration & dosage</topic><topic>Immunoconjugates - adverse effects</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Ki-1 Antigen - immunology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deng, Changchun</creatorcontrib><creatorcontrib>Pan, Beiqing</creatorcontrib><creatorcontrib>O'Connor, Owen A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deng, Changchun</au><au>Pan, Beiqing</au><au>O'Connor, Owen A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brentuximab Vedotin</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2013</date><risdate>2013</risdate><volume>19</volume><issue>1</issue><spage>22</spage><epage>27</epage><pages>22-27</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>Brentuximab vedotin (SGN-35), an intravenously administered CD30-specific antibody-drug conjugate, has recently been approved by the U.S. Food and Drug Administration for two indications, including (i) patients with Hodgkin lymphoma relapsing after autologous stem-cell transplantation (ASCT), or after two multidrug regimens in patients with Hodgkin lymphoma who are not candidates for ASCT; and (ii) patients with systemic anaplastic large cell lymphoma (ALCL) who failed at least one prior multidrug chemotherapy regimen. Patients with Hodgkin lymphoma and ALCL treated with brentuximab vedotin showed markedly high response rates for a single agent, exceeding 70% and 80% for Hodgkin lymphoma and ALCL, respectively. The complete response rate was equally as impressive, at 34% and 57% for Hodgkin lymphoma and ALCL, respectively. Results like these and from many other upcoming clinical trials, in which brentuximab vedotin is being investigated in the frontline setting, promise to profoundly change how we manage the CD30-positive lymphoproliferative malignancies. The mechanism of action, preclinical antitumor activity, and clinical activity of brentuximab vedotin against Hodgkin lymphoma, ALCL, and other CD30-expressing lymphomas are reviewed.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>23155186</pmid><doi>10.1158/1078-0432.ccr-12-0290</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2013, Vol.19 (1), p.22-27 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273200111 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Clinical Trials, Phase II as Topic Drug Evaluation, Preclinical Hematopoietic Stem Cell Transplantation Hodgkin Disease - drug therapy Hodgkin Disease - therapy Humans Immunoconjugates - administration & dosage Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Ki-1 Antigen - immunology Medical sciences Pharmacology. Drug treatments Recurrence Transplantation, Autologous Treatment Outcome |
| title | Brentuximab Vedotin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A25%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brentuximab%20Vedotin&rft.jtitle=Clinical%20cancer%20research&rft.au=Deng,%20Changchun&rft.date=2013&rft.volume=19&rft.issue=1&rft.spage=22&rft.epage=27&rft.pages=22-27&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.ccr-12-0290&rft_dat=%3Cproquest_cross%3E1273200111%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273200111&rft_id=info:pmid/23155186&rfr_iscdi=true |